Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 161

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment Options

Open access
Khan, Saad A., Pruitt, Sandi L., Xuan, Lei, Gerber, David E. · 2016 · JAMA Oncology

Abstract

The emergence of immune checkpoint inhibitors targeting either the programmed death 1 (PD1) or cytotoxic T lymphocyte antigen 4 (CTLA4) axis represents a major therapeutic advance in treating lung cancer and other malignant diseases. These new treatments also convey risks for unpredictable, possibly severe, and potentially irreversible autoimmune toxic events that can have an effect on diverse organ systems. With combination immunotherapy regimens, rates of these events may exceed 50%. 1 To limit risk of immune-related adverse events, clinical trials of immune checkpoint inhibitors have routinely excluded patients with preexisting autoimmune disease, a population estimated to include 20 to 50 million individuals in the United States. 2 To determine the impact of this practice on patient eligibility for immunotherapy, we calculated the prevalence of autoimmune disease among patients diagnosed with lung cancer using a large, representative, population-based data set.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2016.2238

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 161

Metadata

Authors
Khan, S. A., Pruitt, S. L., Xuan, L., & Gerber, D. E.
Venue
JAMA Oncology
Published
2016-11-01
Volume
2
Issue
11
Pages
1507
ISSN
2374-2437 (ISSN-L)
OpenAlex
W2416974268
Cited by
161
References
3
FWCI
9.81
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.